Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis

Zhuxuan Fu¹, Lauren Borho², Sarah E Taylor², Linda E Kelemen³, Anna DeFazio⁴, Penelope M Webb⁵, Martin Köbel⁶, Nicola S Meagher⁷, Renhua Na⁵, Antonis C Antoniou⁸, Alison H Brand⁹, Catherine J Kennedy¹⁰, Nikilyn Nevins¹⁰, Paul D P Pharoah¹¹, Yurii B Shvetsov¹², Stacey J Winham¹³, Jennifer Alsop¹⁴, Matthias W Beckmann¹⁵, Adelyn Bolithon¹⁶, Jessica Boros¹⁰, David D L Bowtell¹⁷, James D Brenton¹⁸, Michael E Carney¹⁹, Anita Chudecka-Głaz²⁰, Linda S Cook²¹, Cezary Cybulski²², Peter A Fasching¹⁵, Sian Fereday¹⁷, Renée T Fortner²³, María J García²⁴, Ellen L Goode²⁵, Marc T Goodman²⁶, Jacek Gronwald²⁷, Arndt Hartmann¹⁵, Brenda Y Hernandez¹², Estrid Høgdall²⁸, David G Huntsman²⁹, Allan Jensen³⁰, Mercedes Jimenez-Linan³¹, Janine M Joseph³², Beth Y Karlan³³, Ewa Kaznowska³⁴, Susanne K Kjaer³⁵, Tomasz Kluz³⁶, Jennifer M Koziak³⁷, Jenny Lester³³, Teri A Longacre³⁸, Maria Lycke³⁹, Valerie McGuire⁴⁰, Kirsten B Moysich³², Rachel A Murphy⁴¹, Sandra Orsulic³³, Susan J Ramus¹⁶, Cristina Rodríguez-Antona⁴², Joseph H Rothstein⁴³, Spinder Samra⁴⁴, Weiva Sieh⁴⁵, Helen Steed⁴⁶, Karin Sundfeldt⁴⁷, Aline Talhouk⁴⁸, Jan Uciński²⁰, Chen Wang¹³, Nicolas Wentzensen⁴⁹, Alice S Whittemore⁵⁰, Lynne R Wilkens¹², Thomas Songer⁵¹, Maria Mori Brooks⁵¹, Lu Tang⁵², Francesmary Modugno⁵³

Affiliations

¹ Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA 15213, USA; St. Luke's Mid America Heart Institute. St Luke's Health System. Kansas City, MO, USA.
² Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences. University of Pittsburgh School of Medicine. Pittsburgh, PA 15213, USA.
³ South Carolina Department of Public Health. Columbia, SC, USA.
⁴ Centre for Cancer Research. The Westmead Institute for Medical Research. Sydney, New South Wales 2145, Australia; Faculty of Medicine and Health. The University of Sydney. Sydney, New South Wales 2006, Australia.; Department of Gynaecological Oncology. Westmead Hospital. Sydney, New South Wales 2145, Australia; The Daffodil Centre, The University of Sydney. A Joint Venture with Cancer Council NSW. Sydney, New South Wales 2006, Australia.
⁵ Population Health Program. QIMR Berghofer. Brisbane, Queensland 4006, Australia; School of Public Health. The University of Queensland. Brisbane 4006, Australia.
⁶ Department of Pathology and Laboratory Medicine. University of Calgary, Foothills Medical Center. Calgary, AB T2N 2T9, Canada.
⁷ The Daffodil Centre, The University of Sydney. A Joint Venture with Cancer Council NSW. Sydney, New South Wales 2006, Australia; School of Clinical Medicine, UNSW Medicine and Health. University of NSW Sydney. Sydney, New South Wales 2052, Australia.
⁸ Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care. University of Cambridge. Cambridge CB1 8RN, UK.
⁹ Faculty of Medicine and Health. The University of Sydney. Sydney, New South Wales 2006, Australia.; Department of Gynaecological Oncology. Westmead Hospital. Sydney, New South Wales 2145, Australia.
¹⁰ Centre for Cancer Research. The Westmead Institute for Medical Research. Sydney, New South Wales 2145, Australia; Faculty of Medicine and Health. The University of Sydney. Sydney, New South Wales 2006, Australia.; Department of Gynaecological Oncology. Westmead Hospital. Sydney, New South Wales 2145, Australia.
¹¹ Department of Computational Biomedicine. Cedars-Sinai Medical Center. West Hollywood, CA 90069, USA.
¹² University of Hawaii Cancer Center. Honolulu, HI, USA.
¹³ Department of Quantitative Health Sciences, Division of Computational Biology. Mayo Clinic. Rochester, MN 55905, USA.
¹⁴ Center for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK.
¹⁵ Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg. University Hospital Erlangen. Erlangen 91054, Germany.
¹⁶ School of Clinical Medicine, UNSW Medicine and Health. University of NSW Sydney. Sydney, New South Wales 2052, Australia; Adult Cancer Program, Lowy Cancer Research Centre. University of NSW Sydney. Sydney, New South Wales 2052, Australia.
¹⁷ Peter MacCallum Cancer Centre. Melbourne, Victoria 3000, Australia; Sir Peter MacCallum Department of Oncology. The University of Melbourne. Parkville, Victoria 3010, Australia.
¹⁸ Cancer Research UK Cambridge Institute, University of Cambridge. Cambridge CB2 0RE, UK.
¹⁹ Department of Obstetrics and Gynecology, John A. Burns School of Medicine. University of Hawaii. Honolulu, HI, USA.
²⁰ Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents. Pomeranian Medical University. Szczecin 70-111, Poland.
²¹ Epidemiology, School of Public Health, University of Colorado. Aurora, CO, USA; Community Health Sciences. University of Calgary. Calgary, AB, Canada.
²² International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
²³ Division of Cancer Epidemiology. German Cancer Research Center (DKFZ). Heidelberg 69120, Germany; Department of Research, Cancer Registry of Norway. Norwegian Institute of Public Health. Oslo, Norway.
²⁴ Genomic Biomarkers and Precision Oncology Laboratory, Cancer Department. Sols-Morreale Biomedical Research Institute (IIBM), CSIC-UAM. Madrid, Spain.
²⁵ Department of Quantitative Health Sciences, Division of Epidemiology. Mayo Clinic. Rochester, MN 55905, USA.
²⁶ Cancer Prevention and Control Program, Cedars-Sinai Cancer. Cedars-Sinai Medical Center. Los Angeles, CA 90048, USA.
²⁷ Department of Genetics and Pathology. Pomeranian Medical University. Szczecin 71-252, Poland.
²⁸ Department of Pathology, Herlev Hospital. University of Copenhagen. Copenhagen DK-2100, Denmark.
²⁹ Department of Obstetrics and Gynecology. University of British Columbia. Vancouver, BC V5Z 1L3, Canada; Department of Molecular Oncology. BC Cancer Research Centre. Vancouver, BC V5Z 4E6, Canada.
³⁰ Department of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen DK-2100, Denmark.
³¹ Department of Histopathology. Addenbrooke's Hospital. Cambridge, UK.
³² Department of Cancer Prevention and Control. Roswell Park Comprehensive Cancer Center. Buffalo, NY 14263, USA.
³³ David Geffen School of Medicine, Department of Obstetrics and Gynecology. University of California at Los Angeles. Los Angeles, CA 90095, USA.
³⁴ Department of Pathology, Faculty of Medicine, University of Rzeszow. 35-559 Rzesow, Poland.
³⁵ Department of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen DK-2100, Denmark; Department of Gynaecology, Rigshospitalet. University of Copenhagen. Copenhagen DK-2100, Denmark.
³⁶ Department of Gynecology, Gynecology Oncology and Obstetrics. Institute of Medical Sciences, Medical College of Rzeszow University. Rzesz-w: Poland.
³⁷ Department of Obstetrics and Gynaecology. University of Calgary. Calgary, AB, Canada.
³⁸ Department of Pathology. Stanford University School of Medicine. Stanford, CA 94305, USA.
³⁹ Department of Obstetrics and Gynecology, Institute of Clinical Science. Sahlgrenska University hospital, University of Gothenburg. Gothenburg: Sweden.
⁴⁰ Department of Epidemiology and Population Health. Stanford University School of Medicine. Stanford, CA 94305, USA; Department of Epidemiology and Biostatistics. University of California San Francisco. San Francisco, CA 94158, USA.
⁴¹ School of Population and Public Health. University of British Columbia. Vancouver, BC V6T 1Z4, Canada; Cancer Control Research. BC Cancer Agency. Vancouver, BC V5Z 1L3, Canada.
⁴² Pharmacogenomics and Tumour Biomarkers Laboratory, Cancer Department. Sols-Morreale Biomedical Research Institute (IIBM), CSIC-UAM. Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III. Madrid 28029, Spain.
⁴³ Department of Epidemiology. University of Texas MD Anderson Cancer Center. Houston, TX 77030, USA; Department of Population Health Science and Policy. Icahn School of Medicine at Mount Sinai. New York, NY 10029, USA.
⁴⁴ Faculty of Medicine and Health. The University of Sydney. Sydney, New South Wales 2006, Australia.; Department of Tissue Pathology and Diagnostic Oncology, ICPMR West Mead Hospital, New South Wales, Australia.
⁴⁵ Department of Epidemiology. University of Texas MD Anderson Cancer Center. Houston, TX 77030, USA; Department of Genetics and Genomic Sciences. Icahn School of Medicine at Mount Sinai. New York, NY 10029, USA.
⁴⁶ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology. University of Alberta. Edmonton, Alberta T5H 3V9, Canada; Section of Gynecologic Oncology Surgery, North Zone. Alberta Health Services. Edmonton, Alberta, Canada.
⁴⁷ Department of Obstetrics and Gynecology, Institute of Clinical Science, Sahlgrenska Center for Cancer Research. University of Gothenburg. Gothenburg, Sweden.
⁴⁸ Department of Obstetrics and Gynecology. University of British Columbia. Vancouver, BC V5Z 1L3, Canada; British Columbia's Gynecological Cancer Research Team (OVCARE). University of British Columbia, BC Cancer, and Vancouver General Hospital. Vancouver, BC V5Z 4E6, Canada.
⁴⁹ Division of Cancer Epidemiology and Genetics. National Cancer Institute. Bethesda, MD 20892, USA.
⁵⁰ Department of Epidemiology and Population Health. Stanford University School of Medicine. Stanford, CA 94305, USA; Department of Biomedical Data Science. Stanford University School of Medicine. Stanford, CA 94305, USA.
⁵¹ Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA 15213, USA.
⁵² Department of Biostatistics. University of Pittsburgh Graduate School of Public Health. Pittsburgh, PA, USA.
⁵³ Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA 15213, USA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences. University of Pittsburgh School of Medicine. Pittsburgh, PA 15213, USA; Women's Cancer Research Center. Magee-Womens Research Institute and Hillman Cancer Center. Pittsburgh 15213, PA, USA; Department of Biomedical Informatics. University of Pittsburgh School of Medicine. Pittsburgh, PA 15213, USA. Electronic address: modugnof@upmc.edu.

PMID: 40482607
DOI: 10.1016/j.ygyno.2025.05.013

Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis

Zhuxuan Fu et al. Gynecol Oncol. 2025 Jul.

. 2025 Jul:198:112-129.

doi: 10.1016/j.ygyno.2025.05.013. Epub 2025 Jun 6.

Authors

Affiliations

¹ Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA 15213, USA; St. Luke's Mid America Heart Institute. St Luke's Health System. Kansas City, MO, USA.
² Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences. University of Pittsburgh School of Medicine. Pittsburgh, PA 15213, USA.
³ South Carolina Department of Public Health. Columbia, SC, USA.
⁴ Centre for Cancer Research. The Westmead Institute for Medical Research. Sydney, New South Wales 2145, Australia; Faculty of Medicine and Health. The University of Sydney. Sydney, New South Wales 2006, Australia.; Department of Gynaecological Oncology. Westmead Hospital. Sydney, New South Wales 2145, Australia; The Daffodil Centre, The University of Sydney. A Joint Venture with Cancer Council NSW. Sydney, New South Wales 2006, Australia.
⁵ Population Health Program. QIMR Berghofer. Brisbane, Queensland 4006, Australia; School of Public Health. The University of Queensland. Brisbane 4006, Australia.
⁶ Department of Pathology and Laboratory Medicine. University of Calgary, Foothills Medical Center. Calgary, AB T2N 2T9, Canada.
⁷ The Daffodil Centre, The University of Sydney. A Joint Venture with Cancer Council NSW. Sydney, New South Wales 2006, Australia; School of Clinical Medicine, UNSW Medicine and Health. University of NSW Sydney. Sydney, New South Wales 2052, Australia.
⁸ Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care. University of Cambridge. Cambridge CB1 8RN, UK.
⁹ Faculty of Medicine and Health. The University of Sydney. Sydney, New South Wales 2006, Australia.; Department of Gynaecological Oncology. Westmead Hospital. Sydney, New South Wales 2145, Australia.
¹⁰ Centre for Cancer Research. The Westmead Institute for Medical Research. Sydney, New South Wales 2145, Australia; Faculty of Medicine and Health. The University of Sydney. Sydney, New South Wales 2006, Australia.; Department of Gynaecological Oncology. Westmead Hospital. Sydney, New South Wales 2145, Australia.
¹¹ Department of Computational Biomedicine. Cedars-Sinai Medical Center. West Hollywood, CA 90069, USA.
¹² University of Hawaii Cancer Center. Honolulu, HI, USA.
¹³ Department of Quantitative Health Sciences, Division of Computational Biology. Mayo Clinic. Rochester, MN 55905, USA.
¹⁴ Center for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK.
¹⁵ Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg. University Hospital Erlangen. Erlangen 91054, Germany.
¹⁶ School of Clinical Medicine, UNSW Medicine and Health. University of NSW Sydney. Sydney, New South Wales 2052, Australia; Adult Cancer Program, Lowy Cancer Research Centre. University of NSW Sydney. Sydney, New South Wales 2052, Australia.
¹⁷ Peter MacCallum Cancer Centre. Melbourne, Victoria 3000, Australia; Sir Peter MacCallum Department of Oncology. The University of Melbourne. Parkville, Victoria 3010, Australia.
¹⁸ Cancer Research UK Cambridge Institute, University of Cambridge. Cambridge CB2 0RE, UK.
¹⁹ Department of Obstetrics and Gynecology, John A. Burns School of Medicine. University of Hawaii. Honolulu, HI, USA.
²⁰ Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents. Pomeranian Medical University. Szczecin 70-111, Poland.
²¹ Epidemiology, School of Public Health, University of Colorado. Aurora, CO, USA; Community Health Sciences. University of Calgary. Calgary, AB, Canada.
²² International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
²³ Division of Cancer Epidemiology. German Cancer Research Center (DKFZ). Heidelberg 69120, Germany; Department of Research, Cancer Registry of Norway. Norwegian Institute of Public Health. Oslo, Norway.
²⁴ Genomic Biomarkers and Precision Oncology Laboratory, Cancer Department. Sols-Morreale Biomedical Research Institute (IIBM), CSIC-UAM. Madrid, Spain.
²⁵ Department of Quantitative Health Sciences, Division of Epidemiology. Mayo Clinic. Rochester, MN 55905, USA.
²⁶ Cancer Prevention and Control Program, Cedars-Sinai Cancer. Cedars-Sinai Medical Center. Los Angeles, CA 90048, USA.
²⁷ Department of Genetics and Pathology. Pomeranian Medical University. Szczecin 71-252, Poland.
²⁸ Department of Pathology, Herlev Hospital. University of Copenhagen. Copenhagen DK-2100, Denmark.
²⁹ Department of Obstetrics and Gynecology. University of British Columbia. Vancouver, BC V5Z 1L3, Canada; Department of Molecular Oncology. BC Cancer Research Centre. Vancouver, BC V5Z 4E6, Canada.
³⁰ Department of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen DK-2100, Denmark.
³¹ Department of Histopathology. Addenbrooke's Hospital. Cambridge, UK.
³² Department of Cancer Prevention and Control. Roswell Park Comprehensive Cancer Center. Buffalo, NY 14263, USA.
³³ David Geffen School of Medicine, Department of Obstetrics and Gynecology. University of California at Los Angeles. Los Angeles, CA 90095, USA.
³⁴ Department of Pathology, Faculty of Medicine, University of Rzeszow. 35-559 Rzesow, Poland.
³⁵ Department of Virus, Lifestyle and Genes, Danish Cancer Institute, Copenhagen DK-2100, Denmark; Department of Gynaecology, Rigshospitalet. University of Copenhagen. Copenhagen DK-2100, Denmark.
³⁶ Department of Gynecology, Gynecology Oncology and Obstetrics. Institute of Medical Sciences, Medical College of Rzeszow University. Rzesz-w: Poland.
³⁷ Department of Obstetrics and Gynaecology. University of Calgary. Calgary, AB, Canada.
³⁸ Department of Pathology. Stanford University School of Medicine. Stanford, CA 94305, USA.
³⁹ Department of Obstetrics and Gynecology, Institute of Clinical Science. Sahlgrenska University hospital, University of Gothenburg. Gothenburg: Sweden.
⁴⁰ Department of Epidemiology and Population Health. Stanford University School of Medicine. Stanford, CA 94305, USA; Department of Epidemiology and Biostatistics. University of California San Francisco. San Francisco, CA 94158, USA.
⁴¹ School of Population and Public Health. University of British Columbia. Vancouver, BC V6T 1Z4, Canada; Cancer Control Research. BC Cancer Agency. Vancouver, BC V5Z 1L3, Canada.
⁴² Pharmacogenomics and Tumour Biomarkers Laboratory, Cancer Department. Sols-Morreale Biomedical Research Institute (IIBM), CSIC-UAM. Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III. Madrid 28029, Spain.
⁴³ Department of Epidemiology. University of Texas MD Anderson Cancer Center. Houston, TX 77030, USA; Department of Population Health Science and Policy. Icahn School of Medicine at Mount Sinai. New York, NY 10029, USA.
⁴⁴ Faculty of Medicine and Health. The University of Sydney. Sydney, New South Wales 2006, Australia.; Department of Tissue Pathology and Diagnostic Oncology, ICPMR West Mead Hospital, New South Wales, Australia.
⁴⁵ Department of Epidemiology. University of Texas MD Anderson Cancer Center. Houston, TX 77030, USA; Department of Genetics and Genomic Sciences. Icahn School of Medicine at Mount Sinai. New York, NY 10029, USA.
⁴⁶ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology. University of Alberta. Edmonton, Alberta T5H 3V9, Canada; Section of Gynecologic Oncology Surgery, North Zone. Alberta Health Services. Edmonton, Alberta, Canada.
⁴⁷ Department of Obstetrics and Gynecology, Institute of Clinical Science, Sahlgrenska Center for Cancer Research. University of Gothenburg. Gothenburg, Sweden.
⁴⁸ Department of Obstetrics and Gynecology. University of British Columbia. Vancouver, BC V5Z 1L3, Canada; British Columbia's Gynecological Cancer Research Team (OVCARE). University of British Columbia, BC Cancer, and Vancouver General Hospital. Vancouver, BC V5Z 4E6, Canada.
⁴⁹ Division of Cancer Epidemiology and Genetics. National Cancer Institute. Bethesda, MD 20892, USA.
⁵⁰ Department of Epidemiology and Population Health. Stanford University School of Medicine. Stanford, CA 94305, USA; Department of Biomedical Data Science. Stanford University School of Medicine. Stanford, CA 94305, USA.
⁵¹ Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA 15213, USA.
⁵² Department of Biostatistics. University of Pittsburgh Graduate School of Public Health. Pittsburgh, PA, USA.
⁵³ Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA 15213, USA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences. University of Pittsburgh School of Medicine. Pittsburgh, PA 15213, USA; Women's Cancer Research Center. Magee-Womens Research Institute and Hillman Cancer Center. Pittsburgh 15213, PA, USA; Department of Biomedical Informatics. University of Pittsburgh School of Medicine. Pittsburgh, PA 15213, USA. Electronic address: modugnof@upmc.edu.

PMID: 40482607
DOI: 10.1016/j.ygyno.2025.05.013

Abstract

Objective: Many epithelial ovarian cancer (EOC) risk factors relate to sex hormones. The association between these factors and the expression of androgen receptor (AR), estrogen receptor-α (ER), and progesterone receptor (PR) in tumors is unknown.

Method: We linked epidemiologic, AR/ER/PR tumor expression, and survival data from 19 studies in the Ovarian Cancer Association Consortium (OCAC; 4762 cases, 20,888 controls) and the Ovarian Tumor Tissue Analysis (OTTA) consortium (5737 cases). We estimated odds ratios (ORs) and 95 % confidence intervals (CIs) between hormonally-linked factors and tumor AR/ER/PR expression using polytomous logistic regression. We assessed survival by AR/ER/PR tumor expression overall and by histotype using Kaplan-Meier curves and Cox proportional hazards models.

Results: Overweight/obesity was associated with higher risk of ER- tumors (OR:1.53, 95 % I:1.18-1.98). Hysterectomy was associated with greater risk of ER+ tumors (OR:4.99, 95 % CI:4.27-5.83), which varied by AR expression (P_heter=0.003). Postmenopause was associated with a higher risk of PR- tumors (OR 1.52, 95 % CI 1.26-1.83), which varied based by AR (P_heter < 0.001) and ER (P_heter < 0.001) expression. Gravidity, oral contraception duration, and breastfeeding duration showed differing dose-response relationships according to AR/ER/PR expression. Hormone therapy use, postmenopause, physical inactivity, and being obese/overweight prior to diagnosis were differentially associated with survival based on AR/ER/PR expression and histotype.

Conclusion: EOC has varying risk and prognostic profiles depending on both histotype and AR/ER/PR expression. Biological mechanisms underlying the association between hormonally-linked factors and EOC need to be studied by both histotypes and by AR, ER, and PR expression.

Keywords: Epithelial ovarian cancer; Hormonal factors; Hormone receptor; Risk; Survival; androgen receptor; estrogen receptor; progesterone receptor.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Jessica Boros: Cancer Institute New South Wales, National Health and Medical Research Council of Australia, Department of Gynecological Oncology, Westmead Hospital, NSW, The Westmead Institute for Medical Research. Alison Brand: Board of Directors of ANZGOG and GCIG, Data Safety Management Board for DEBULK. Anna DeFazio: Research support from AstraZeneca, Illumina. Sian Fereday: AstraZeneca Pty Ltd. – Research Grant to AOCS. Maria J. Garcia: Proyect Grant from Ministerio de Ciencia, Innovación y Universidades. Ellen Goode: Mayo Foundation; Minnesota. Arndt Hartmann: AstraZeneca, Biocartis, Cepheid, Gilead, Illumina, Janssen, Novartis, Owkin, Qiagen, QUIP GmbH – payments to the institution. Beth Karlan: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN); UCLA Clinical and Translational Science Institute – Precision Health; Independent Data Monitoring Committee – GRAIL PATHFINDER; Scientific Advisor to Ovarian Cancer Research Alliance (OCRA) and American Cancer Society (ACS) BrightEdge. Catherine Jane Kennedy: Australian National Health and Medical Research Council, Cancer Institute NSW – grant payments to my institution. Martin Kobel: Payments from Astra Zeneca, GSK, Merck, AbbVie, Helix biopharma. Renhua Na: NHMRC Program Grant (GNT1073898). Niklyn Nevins: Research support from Illumina. Christina Rodriguez-Antona: Grant PID2021-1283120B-100, funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe. Penelope M. Webb: U.S. Army Medical Research and Material Command, National Health & Medical Research Council of Australia, Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia – Grants to institution. All other authors declare no conflicts of interest.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis

Affiliations

Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis

Authors

Affiliations

Abstract

Conflict of interest statement

MeSH terms

Substances

Grants and funding